Comparing the current results to its competitors, Aquestive Therapeutics Inc reported Revenue increase in the 1 quarter 2026 by 65.67 % year on year. The sales growth was above Aquestive Therapeutics Inc 's competitors' average revenue growth of 20.66 %, achieved in the same quarter.
Aquestive Therapeutics Inc , slower than the average decrease reported by the company's competitors of -31.97 %. recorded a net loss and most of the company's competitors saw a decline in earnings by -31.97 %
Aquestive Therapeutics Inc 's Comment on Competition and Industry Peers
The company operates in a highly competitive pharmaceutical and biotechnology market, developing therapeutics across various disease areas and indications. Competition includes firms utilizing advanced drug administration platforms such as oral, injectable, intranasal, transdermal patch, and pulmonary delivery. Competitors range from multinational organizations and established biotechnology companies to single-product pharmaceutical and biotechnology firms, specialty pharmaceutical companies, and generic drug manufacturers. Key factors influencing competition include efficacy, safety, convenience, ease of use, companion diagnostics, generic competition, and reimbursement availability. In the treatment of anaphylaxis, if approved by the FDA, the company anticipates competing with existing products and candidates targeting Type I allergic reactions, including needle device-based treatments like autoinjectors such as EpiPen, marketed by Teva.
Due to outstanding performance in Overall company, revenue grew by 65.67 % Aquestive Therapeutics Inc improved its market share, to approximately 0.01 %.
October 8, 2025
Aquestive Therapeutics Expands Intellectual Property for Anaphylm Amidst Challenging Financial Landscape Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company known for pioneering advanced medication delivery technologies, has announced a significant expansion of its intellectual property portfolio. According to a recent press release dated October 8, 2025, the United States Patent and Trademark Office (USPTO) has granted two new U.S. patents associated with Anaphylm, Aquestive s novel epinephrine prodrug sublingual film. This development underscores the company s commitment to innovation and delivering transformative healthcare solutions. Anaphylm and Its PotentialAnaphylm represents a break...
April 29, 2024
Aquestive Therapeutics Receives U.S. FDA Approval and Market Access for Libervant (diazepam) Buccal Film in Pediatric Patients Ages 2 to 5 and Provides Update on Anaphylm (epinephrine) Sublingual FilmWARREN, N.J., April 29, 2024 - Aquestive Therapeutics, a leading pharmaceutical company focused on innovative science and delivery technologies, has made significant advancements in improving the lives of young patients suffering from epilepsy. The company recently announced that the U.S. Food and Drug Administration (FDA) has approved their product Libervant (diazepam) Buccal Film for the acute treatment of frequent and distinct episodes of seizure activity, often referred to as seizure clusters or acute repeti...
March 14, 2024
Aquestive Therapeutics, a leading pharmaceutical company focused on developing innovative science and delivery technologies, recently announced positive topline clinical data from its Phase 3 pivotal pharmacokinetic (PK) clinical study of Anaphylm (epinephrine) Sublingual Film. This groundbreaking product represents the company s first orally administered epinephrine prodrug candidate for the treatment of severe life-threatening allergic reactions, including anaphylaxis. In addition to the study results, the company also presented key findings from their meeting with the U.S. Food and Drug Administration (FDA).The Need for an Oral Epinephrine Prodrug:Epinephrine, commonly administered via auto-injectors, is ...
February 15, 2024
Aquestive Therapeutics Presents Positive Pharmacokinetic and Pharmacodynamic Data for Anaphylm at AAAAI Annual MeetingWarren, N.J., (Date) - Aquestive Therapeutics, a leading pharmaceutical company dedicated to advancing medicines that significantly improve patients lives through innovative science and delivery technologies, has announced the presentation of compelling pharmacokinetic (PK) and pharmacodynamic (PD) data for Anaphylm at the American Academy of Allergy, Asthma, and Immunology (AAAAI) 2024 annual meeting. The poster presentation will highlight the results of two completed clinical studies, revealing that Anaphylm s performance is comparable to epinephrine delivered via autoinjector or manual in...
Publicly Traded Peers of Aquestive Therapeutics Inc
Renovorx Inc Share Performance
+78.70%
One Year
Renovorx Inc
Profile
Renovorx Inc is a medical technology company specializing in the development of innovative treatments for cardiovascular diseases. Their business model focuses on creating and commercializing minimally invasive therapies for patients suffering from conditions like myocardial infarction and heart failure. By leveraging cutting-edge medical devices and procedures, Renovorx aims to provide effective and efficient treatments that can significantly improve patient outcomes and quality of life.
Royalty Pharma Plc operates as a pharmaceutical investment company, focusing on acquiring and managing royalty interests in approved drugs. Their business model primarily revolves around purchasing existing royalty streams in exchange for upfront payments, allowing them to generate ongoing cash flows from the sales of these drugs. They aim to provide liquidity to stakeholders, such as biotech and pharmaceutical companies, by offering a financial alternative to traditional financing options.
Sage Therapeutics Inc's business model primarily revolves around researching, developing, and commercializing innovative therapies for various central nervous system disorders. The company focuses on discovering novel molecules and applying them to create targeted treatments that address the unmet medical needs of patients. By harnessing scientific advancements and strategic collaborations, Sage aims to deliver transformative therapies for individuals suffering from conditions such as depression, postpartum depression, and other mood disorders.
Scpharmaceuticals Inc's business model involves the development and commercialization of innovative pharmaceutical products. They aim to create and bring to market novel therapies that improve patient access, safety, and convenience. Their approach focuses on leveraging their proprietary technology to develop and deliver drugs in a unique and effective manner.
Acelyrin Inc is a technology company that focuses on providing cutting-edge solutions in the healthcare industry. Their business model is centered around developing innovative software and hardware products that improve patient outcomes, enhance operational efficiency, and drive cost savings for healthcare organizations. By offering a range of advanced tools and services, Acelyrin Inc aims to revolutionize the healthcare sector and contribute to the overall advancement of digital health.
Sources:
Aquestive Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Aquestive Therapeutics Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
